Scholarlink

<p>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease increasingly viewed as systemic. Irritable bowel syndrome (IBS) has been proposed as a comorbidity, yet longitudinal data remain limited. A retrospective cohort study was conducted using the U.S. Collaborative Network of the TriNetX platform, including adults diagnosed with HS from 2005–2023 and matched controls without HS. Patients with prior IBS or cancer were excluded. Propensity score matching (1:1) accounted for demographic, socioeconomic, and clinical variables. Incident IBS, defined by ICD-10-CM codes, was assessed over 15&#xa0;years. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated. Sensitivity analyses varied washout periods, follow-up times, and HS definitions; subgroups were stratified by age and sex. The matched cohort comprised 119,848 HS patients and equal controls. HS was associated with greater IBS risk (HR 1.422, 95% CI 1.308–1.547), consistent across sensitivity analyses. Compared with psoriasis, HS conferred higher IBS risk (HR 1.268, 95% CI 1.157–1.390). Age-stratified analyses showed increased risk in both 18–64&#xa0;years (HR 1.538, 95% CI 1.397–1.694) and ≥ 65&#xa0;years (HR 2.443, 95% CI 1.619–3.686). Risk was also elevated in males (HR 1.556, 95% CI 1.221–1.983) and females (HR 1.489, 95% CI 1.354–1.638). HS independently predicts higher long-term IBS risk, supporting shared inflammatory and barrier dysfunction pathways.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Risk of irritable bowel syndrome in patients with hidradenitis suppurativa: a global-federated, multicenter cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月3日

查看全文
  • Hui-Chin Chang,
  • Yi-Hsuan Hsu,
  • Shiu-Jau Chen,
  • Meng-Che Wu,
  • Shuo-Yan Gau

摘要

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease increasingly viewed as systemic. Irritable bowel syndrome (IBS) has been proposed as a comorbidity, yet longitudinal data remain limited. A retrospective cohort study was conducted using the U.S. Collaborative Network of the TriNetX platform, including adults diagnosed with HS from 2005–2023 and matched controls without HS. Patients with prior IBS or cancer were excluded. Propensity score matching (1:1) accounted for demographic, socioeconomic, and clinical variables. Incident IBS, defined by ICD-10-CM codes, was assessed over 15 years. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated. Sensitivity analyses varied washout periods, follow-up times, and HS definitions; subgroups were stratified by age and sex. The matched cohort comprised 119,848 HS patients and equal controls. HS was associated with greater IBS risk (HR 1.422, 95% CI 1.308–1.547), consistent across sensitivity analyses. Compared with psoriasis, HS conferred higher IBS risk (HR 1.268, 95% CI 1.157–1.390). Age-stratified analyses showed increased risk in both 18–64 years (HR 1.538, 95% CI 1.397–1.694) and ≥ 65 years (HR 2.443, 95% CI 1.619–3.686). Risk was also elevated in males (HR 1.556, 95% CI 1.221–1.983) and females (HR 1.489, 95% CI 1.354–1.638). HS independently predicts higher long-term IBS risk, supporting shared inflammatory and barrier dysfunction pathways.